MEDIROM Healthcare Technologies reported total revenues of ¥3.48 billion for H1 2024, up 10% YoY from ¥3.15 billion, driven by a 16% increase in directly-operated salon revenue to ¥3.02 billion. However, the company recorded an operating loss of ¥637 million, widening from ¥379 million loss in H1 2023.Total operating expenses increased to ¥4.11 billion from ¥3.53 billion YoY, primarily due to higher costs of directly-operated salons and SG&A expenses. The net loss attributable to shareholders expanded to ¥582 million from ¥355 million in H1 2023. Cash and equivalents stood at ¥145 million as of June 30, 2024.The company made several strategic moves post-period, including establishing MEDIROM Rehab Solutions, signing agreements to acquire 70% stake in Japan Gene Medicine Corporation for ¥2 billion, and securing multiple capital alliances through its subsidiary MEDIROM MOTHER Labs. The company also issued ¥300 million in convertible bonds in October 2024.

MEDIROM Healthcare Technologies reported total revenues of ¥3.48 billion for H1 2024, up 10% YoY from ¥3.15 billion, driven by a 16% increase in directly-operated salon revenue to ¥3.02 billion. However, the company recorded an operating loss of ¥637 million, widening from ¥379 million loss in H1 2023.Total operating expenses increased to ¥4.11 billion from ¥3.53 billion YoY, primarily due to higher costs of directly-operated salons and SG&A expenses. The net loss attributable to shareholders expanded to ¥582 million from ¥355 million in H1 2023. Cash and equivalents stood at ¥145 million as of June 30, 2024.The company made several strategic moves post-period, including establishing MEDIROM Rehab Solutions, signing agreements to acquire 70% stake in Japan Gene Medicine Corporation for ¥2 billion, and securing multiple capital alliances through its subsidiary MEDIROM MOTHER Labs. The company also issued ¥300 million in convertible bonds in October 2024.